Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30121% above fair value
$23.04−0.92 (-3.84%)
Close on Nov 13, 2026Market cap $6.51BP/E –Yield –
Caris Life Sciences operating margin
Operating margin is operating income as a percentage of revenue.
Caris Life Sciences's operating margin for the twelve months ending Sep 30, 2026 was 13.4%. For fiscal 2025 it was 5.6%, against -62.4% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.6% | +67.9 |
| FY2024 | Dec 31, 2024 | -62.4% | +42.0 |
| FY2023 | Dec 31, 2023 | -104.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 7.0% | −8.0 |
| Q2 FY2026 | Jun 30, 2026 | 10.2% | +20.1 |
| Q1 FY2026 | Mar 31, 2026 | 2.4% | +50.4 |
| Q4 FY2025 | Dec 31, 2025 | 30.2% | +58.7 |
| Q3 FY2025 | Sep 30, 2025 | 15.1% | +74.9 |
| Q2 FY2025 | Jun 30, 2025 | -9.9% | +57.1 |
| Q1 FY2025 | Mar 31, 2025 | -47.9% | – |
| Q4 FY2024 | Dec 31, 2024 | -28.5% | – |
| Q3 FY2024 | Sep 30, 2024 | -59.9% | – |
| Q2 FY2024 | Jun 30, 2024 | -67.0% | – |
See a number that looks wrong?